UAB has a thriving neuroscience research community, centered in the Comprehensive Neuroscience Center (CNC).  The Center for Neurodegeneration and Experimental Therapeutics (CNET) is dedicated to laboratory research on AD and other neurodegenerative diseases, including identification of novel therapeutics, and to training the next generation of basic AD researchers.

Among the many active areas of laboratory research in AD at UAB are:

• Role of tau in AD and development of novel tau-directed therapeutics, in the lab of Dr. Erik Roberson
• Rho kinase (ROCK) as a therapeutic target in AD, in the lab of Dr. Jeremy Herskowitz
• Epigenetic changes in AD, in the labs of Dr. Jeremy Day and Dr. Farah Lubin
• Synaptic dysfunction in AD, in the lab of Dr. Lori McMahon
• Targeting adrenergic receptors in AD, in the lab of Dr. Qin Wang
• Cerebral amyloid amgiopathy and cognitive dysfunction, in the lab of Dr. Thomas van Groen
• Hypertension and vascular risk factors and AD, in the lab of Dr. Inga Kadisha
• Effects of AD on circadian rythyms and sleep in AD, in the lab of Dr. Karen Gamble
• Regulating proteosomal degradation of AD-related proteins, in the lab of Dr. Scott Wilson
• Role of 14-3-3 proteins in Alzheimer’s disease, in the lab of Dr. Talene Yacoubian